It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Some features of ATS will be disabled while you continue to use an ad-blocker.
Independent experts have condemned the Swiss pharmaceuticals company Novartis for trying to force the NHS to buy an expensive drug to treat patients suffering from a degenerative eye disease, rather than using a cheaper, unlicensed alternative.
Novartis says Avastin is unlicensed for the eye disease and wants its own licensed drug Lucentis, which costs £740 an injection compared with £60, to be used.